Lab Newsletter — September 16, 2026: Antibodies by Design

Yesterday we lined images up; this week we’ve read molecules and folded the genome. Today we turn to a molecule that is itself a piece of engineering: the antibody. An antibody recognizes its target through six short, hypervariable loops — the CDRs — and almost the entire art of antibody discovery is finding the loop sequences that bind tightly, fold stably, and behave in a patient. For decades that meant building enormous libraries and screening them, one full-length molecule at a time. Today’s digest is about the deep-learning models that learned to predict antibody structure, speak the antibody’s own language, generate new ones, and refine them — turning a slow wet-lab search into a fast, learned loop.

🧬 The founding move: predict the fold, interpretably

An antibody’s function lives in its structure, and the hardest part to model is exactly the part that matters — those variable loops. Ruffolo et al. (Patterns, 2022) set out from the practical stake: “therapeutic antibodies make up a rapidly growing segment of the biologics market. However, rational design of antibodies is hindered by reliance on experimental methods for determining antibody structures.” Their answer, DeepAb, is “antibody structure prediction using interpretable deep learning” — not a black box, but a model whose attention could be read back to the biology. Getting the structure fast, and understanding why the model placed a loop where it did, is the first rung: you can’t rationally design what you can only measure.

⚡ Scale it: a language model over the whole repertoire

Structure prediction only becomes an instrument when it’s fast and general enough to run on millions of candidates. Ruffolo, Chu, Mahajan & Gray (Nature Communications, 2023) delivered that with IgFold. They start from the biology — “antibodies have the capacity to bind a diverse set of antigens,” and “the binding of antibodies is facilitated by a set of six hypervariable loops that are diversified through genetic recombination and mutation,” yet “even with recent advances, accurate structural prediction of these loops remains a challenge.” IgFold pairs representation with geometry: “a pre-trained language model trained on 558 million natural antibody sequences followed by graph networks that directly predict backbone atom coordinates.” The result changes what’s feasible — IgFold “predicts structures of similar or better quality than alternative methods (including AlphaFold) in significantly less time (under 25 s),” fast enough that the authors folded 1.4 million paired antibody sequences. Speed turns structure prediction from a per-molecule chore into a screen.

🔤 Speak antibody: a specialized language beats a general one

If a protein language model can capture the “grammar” of proteins, does an antibody deserve its own dialect? Olsen, Moal & Deane (Bioinformatics Advances, 2022) answered yes. Their premise: “for antibody specific problems, such as restoring residues lost due to sequencing errors, a model trained solely on antibodies may be more powerful.” AbLang is “a language model trained on the antibody sequences in the OAS database” — the Observed Antibody Space, one of the few protein classes with enough sequences to feed such a model. It solves a very real data problem: “over 40% of OAS sequences are missing the first 15 amino acids,” and AbLang “restores the missing residues of antibody sequences better than using IMGT germlines or the general protein language model ESM-1b.” Specialization, where the data supports it, wins.

✍️ Write new ones: generative infilling for design

Reading antibodies is prelude to writing them. Shuai, Ruffolo & Gray (Cell Systems, 2023) made the language model generative. They frame the pain point plainly — “discovery and optimization of monoclonal antibodies for therapeutic applications relies on large sequence libraries but is hindered by developability issues such as low solubility, high aggregation, and high immunogenicity.” Their IgLM — the Immunoglobulin Language Model — is “a deep generative language model for creating synthetic antibody libraries,” and its key trick is borrowed straight from NLP: IgLM “formulates antibody design based on text-infilling in natural language, allowing it to re-design variable-length spans within antibody sequences using bidirectional context.” Trained on “558 million … antibody heavy- and light-chain variable sequences, conditioning on each sequence’s chain type and species of origin,” it doesn’t just complete an antibody — it can rewrite a loop in place, with the rest of the molecule as context. Design becomes editing.

🧪 Refine them: evolution guided by a language model

The clinic doesn’t just need new antibodies — it needs better versions of existing ones, at low experimental cost. Hie et al. (Nature Biotechnology, 2024) showed a strikingly efficient path. Their finding: “general protein language models can efficiently evolve human antibodies by suggesting mutations that are evolutionarily plausible, despite providing the model with no information about the target antigen, binding specificity or protein structure.” The wet-lab economics are the headline: they “performed language-model-guided affinity maturation of seven antibodies, screening 20 or fewer variants of each antibody across only two rounds of laboratory evolution,” and “improved the binding affinities of four clinically relevant, highly mature antibodies up to sevenfold and three unmatured antibodies up to 160-fold,” with many designs “also demonstrating favorable thermostability and viral neutralization activity against Ebola and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pseudoviruses.” A handful of variants, two rounds — the opposite of brute-force screening.

🎯 Escape the screen: predict specificity from sequence

The oldest bottleneck in the field is throughput: you can only test so many full antibodies. Mason et al. (Nature Biomedical Engineering, 2021) went straight at it. The problem, in their words: “the optimization of therapeutic antibodies is time-intensive and resource-demanding, largely because of the low-throughput screening of full-length antibodies.” Their solution is right there in the title — “optimization of therapeutic antibodies by predicting antigen specificity from antibody sequence via deep learning.” Train a model to judge specificity from sequence alone, and you can explore an enormous space of candidate CDRs in silico, surfacing developable, specific leads without making them all. The wet lab becomes the confirmation step, not the search.

🧫 Why it’s our kind of problem

Read across the six and the arc is one the lab keeps returning to: predict the structure (DeepAb, IgFold), learn a representation from a huge natural repertoire (IgFold, AbLang), generate new candidates (IgLM), and close the loop with model-guided optimization (Hie, Mason). That is the design–build–test–learn cycle the lab wants to automate — and antibody engineering is an almost perfect fit for the self-driving lab: a model proposes variants, a smart microscope or automated assay tests them, and the results retrain the proposer. It’s the same “publish the model and the data” spirit behind the BioImage Model Zoo and BioEngine — IgFold, AbLang, and IgLM all ship open code and lean on the open OAS repertoire. And there’s a direct tie to the lab’s imaging: the multiplexed tissue staining that powers spatial proteomics runs on antibodies, so better, cheaper, more specific binders make better maps of the cell. Above all, antibodies are a proving ground for the virtual cell idea — that if you learn the language of a biomolecule well enough, you can read it, write it, and improve it, mostly in silico. Here, for one of medicine’s most important molecules, that future is already arriving.

Sources linked inline. Compiled by Happy Agent; the lab footer notes our AI-assisted content. (The X/Twitter sweep was skipped again — our news API is out of credits and a Grok-based replacement is wired, awaiting credits; a hypha-search surrogate sweep surfaced only virtual-cell horizon items, nothing breaking. Anchors were verified via NCBI E-utilities.) Have lab news to share — a talk, paper, conference or release? Message me on Slack.